Skye Bioscience (FRA:09R) Cyclically Adjusted FCF per Share: €-9.97 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:09R Skye Bioscience Inc FRA:09R
21 GF Score
Price €0.54
! 1 Warning Sign
View Full Analysis

What is Skye Bioscience Cyclically Adjusted FCF per Share?

Skye Bioscience FRA:09R -3.57% 21 Cyclically Adjusted FCF per Share is €-9.97 as of Mar. 2026. GuruFocus rates FRA:09R with a GF Score™ of 21/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Skye Bioscience's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.187. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-9.97 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 12.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Skye Bioscience was 12.30% per year. The lowest was 12.30% per year. And the median was 12.30% per year.

As of today (2026-07-15), Skye Bioscience's current stock price is €0.54. Skye Bioscience's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-9.97. Skye Bioscience's Cyclically Adjusted Price-to-FCF of today is .


Skye Bioscience  (FRA:09R) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Skye Bioscience Cyclically Adjusted FCF per Share Related Terms


Skye Bioscience Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Skye Bioscience's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Skye Bioscience Cyclically Adjusted FCF per Share Chart

Skye Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -12.08

Skye Bioscience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.60 -15.49 -13.38 -12.08 -9.97

FRA:09R vs PLRZ, NEUP, LGVN: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Skye Bioscience's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Skye Bioscience Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Skye Bioscience's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Skye Bioscience's Cyclically Adjusted Price-to-FCF falls into.


FRA:09R
21GF Score
Skye Bioscience Inc FRA:09R
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Skye Bioscience Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Skye Bioscience's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.187/330.2130*330.2130
=-0.187

Current CPI (Mar. 2026) = 330.2130.

Skye Bioscience Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -13.519 241.018 -18.522
201609 -5.700 241.428 -7.796
201612 -9.828 241.432 -13.442
201703 -8.204 243.801 -11.112
201706 -2.114 244.955 -2.850
201709 -0.694 246.819 -0.928
201712 -14.852 246.524 -19.894
201803 -2.408 249.554 -3.186
201806 -1.740 251.989 -2.280
201809 -1.329 252.439 -1.738
201812 -1.684 251.233 -2.213
201903 -2.384 254.202 -3.097
201906 -1.878 256.143 -2.421
201909 -2.539 256.759 -3.265
201912 -1.930 256.974 -2.480
202003 -1.559 258.115 -1.994
202006 -1.247 257.797 -1.597
202009 -1.629 260.280 -2.067
202012 -1.221 260.474 -1.548
202103 -0.846 264.877 -1.055
202106 -0.915 271.696 -1.112
202109 -0.776 274.310 -0.934
202112 -0.901 278.802 -1.067
202203 -1.336 287.504 -1.534
202206 -1.385 296.311 -1.543
202209 -1.052 296.808 -1.170
202212 -1.572 296.797 -1.749
202303 -1.007 301.836 -1.102
202306 -0.473 305.109 -0.512
202309 -0.483 307.789 -0.518
202312 -0.286 306.746 -0.308
202403 -0.155 312.332 -0.164
202406 -0.171 314.175 -0.180
202409 -0.157 315.301 -0.164
202412 -0.196 315.605 -0.205
202503 -0.214 319.799 -0.221
202506 -0.235 322.561 -0.241
202509 -0.287 324.800 -0.292
202512 -0.210 324.054 -0.214
202603 -0.187 330.213 -0.187

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-9.97 mean?
Skye Bioscience (FRA:09R) has a Cyclically Adjusted FCF per Share of €-9.97 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Skye Bioscience and its competitors.
Is Skye Bioscience's Cyclically Adjusted FCF per Share too high?
Skye Bioscience's current Cyclically Adjusted FCF per Share is €-9.97. Overall, Skye Bioscience has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Skye Bioscience's Cyclically Adjusted FCF per Share compare to PLRZ and NEUP?
Skye Bioscience's Cyclically Adjusted FCF per Share of €-9.97 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Skye Bioscience and its competitors. Skye Bioscience's current Cyclically Adjusted FCF per Share is €-9.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Skye Bioscience stock overvalued right now?
Skye Bioscience (FRA:09R) has a current Cyclically Adjusted FCF per Share of €-9.97. The current Cyclically Adjusted FCF per Share is €-9.97. Skye Bioscience's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Skye Bioscience (FRA:09R), the current Cyclically Adjusted FCF per Share is €-9.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Skye Bioscience Business Description

Other Exchanges SKYE:USA
Address 11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
21GF Score

Get the complete analysis for FRA:09R

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.54
Price